- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 2407
View more information in the IUPHAR Pharmacology Education Project: fingolimod
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|Approved drug?||Yes (FDA (2010), EMA (2011))|
|International Nonproprietary Names|
|FTY-720 | FTY720 | Gilenya®|
|Fingolimod was the first approved oral therapy for multiple sclerosis.
Fingolimod FTY720) is the prodrug of a S1P receptor agonist . When fingolimod binds to S1P1R the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function . Clinical efficacy results from modulation of S1P1 receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on other S1P receptor subtypes.
Selective S1P1R agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.
|CAS Registry No.||162359-55-9 (source: Scifinder)|
|GtoPdb PubChem SID||135650261|
|Search Google for chemical match using the InChIKey||KKGQTZUTZRNORY-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||KKGQTZUTZRNORY|
|Search PubMed clinical trials||fingolimod|
|Search PubMed titles||fingolimod|
|Search PubMed titles/abstracts||fingolimod|
|Search UniChem for chemical match using the InChIKey||KKGQTZUTZRNORY-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||KKGQTZUTZRNORY|